Lawrence D. True

Q: What Schools Are Affiliated With Lawrence D. True

Lawrence D. True is affiliated with the following schools: Yale University, Oregon Health & Science University, University of Washington

Lawrence D. True's AcademicInfluence.com Rankings

Lawrence D. True

Philosophy

#7784

World Rank

#11039

Historical Rank

Logic

#4822

World Rank

#6151

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Lawrence D. True's Degrees

PhD Biomedical Sciences University of California, San Francisco
Bachelors Biochemistry University of California, Berkeley

Why Is Lawrence D. True Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence D. True's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The landscape of somatic copy-number alteration across human cancers (2010) (3297)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder (1998) (1501)
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. (2008) (1370)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009) (891)
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B (2012) (668)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. (2007) (526)
Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. (1999) (514)
Expression profiling reveals hepsin overexpression in prostate cancer. (2001) (407)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. (2017) (407)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. (2018) (401)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
Human cancers express a mutator phenotype (2006) (377)
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. (2014) (364)
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. (2009) (349)
Multicolor quantum dots for molecular diagnostics of cancer (2006) (327)
Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer (2016) (326)
Aggressive Variants of Castration-Resistant Prostate Cancer (2014) (323)
Thyroid Transcription Factor-1 Is Expressed in Extrapulmonary Small Cell Carcinomas but Not in Other Extrapulmonary Neuroendocrine Tumors (2000) (321)
A causal role for ERG in neoplastic transformation of prostate epithelium (2008) (316)
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. (2003) (306)
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. (2002) (295)
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. (2006) (289)
Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. (1996) (260)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer (2016) (255)
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases (2011) (253)
Osteoprotegerin and rank ligand expression in prostate cancer. (2001) (243)
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents (2010) (239)
Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens (2017) (238)
Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate (2008) (233)
Testicular microlithiasis: imaging appearances and pathologic correlation. (1994) (229)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer (2018) (229)
Persistent intraprostatic androgen concentrations after medical castration in healthy men. (2006) (220)
The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. (2000) (213)
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. (2014) (213)
Cell-cell interaction in prostate gene regulation and cytodifferentiation. (1997) (210)
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. (2010) (203)
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling (2011) (188)
The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder (1990) (187)
Differential expression of osteonectin/SPARC during human prostate cancer progression. (2000) (174)
LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics (2017) (172)
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. (2019) (160)
LuCaP 35: A new model of prostate cancer progression to androgen independence (2003) (157)
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. (1996) (151)
Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors (2014) (150)
Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. (2004) (144)
Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists. (1994) (138)
Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. (2000) (136)
Histopathological assessment of prostate cancer bone osteoblastic metastases. (2008) (133)
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. (2016) (130)
Genomic and phenotypic heterogeneity in prostate cancer (2020) (126)
The androgen‐regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma (2008) (126)
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer (2015) (124)
125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. (2003) (116)
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE) (2008) (115)
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort (2016) (113)
Sequencing small genomic targets with high efficiency and extreme accuracy (2015) (113)
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D (2014) (113)
ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. (2015) (106)
Multi-immersion open-top light-sheet microscope for high-throughput imaging of cleared tissues (2019) (104)
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) (102)
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. (2011) (102)
CD90/THY1 is over-expressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker (2010) (101)
Spermatocytic Seminoma of Testis with Sarcomatous Transformation: A Report of Five Cases (1988) (100)
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) (98)
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases (2007) (97)
The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. (2020) (94)
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients (2003) (94)
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. (1999) (94)
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results (2004) (92)
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling (2021) (87)
Molecular characterization of prostatic small‐cell neuroendocrine carcinoma (2003) (86)
Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. (2008) (85)
Metastases of prostate cancer express estrogen receptor-beta. (2004) (84)
Characterization of prostate cell types by CD cell surface molecules. (2002) (84)
Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. (1990) (83)
TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. (2017) (82)
Quantum dots for molecular pathology: their time has arrived. (2007) (81)
1–125 Versus Pd‐103 for Low‐Risk Prostate Cancer: Morbidity Outcomes from a Prospective Randomized Multicenter Trial (2002) (80)
Unusual causes of increased vascular impedance in renal transplants: duplex Doppler evaluation. (1988) (79)
Quality control in molecular immunohistochemistry (2008) (79)
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. (2019) (78)
Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH (2016) (77)
Application of affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression (2005) (76)
Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer (2007) (73)
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. (2009) (72)
Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 (2007) (72)
Loss of stearoyl‐CoA desaturase expression is a frequent event in prostate carcinoma (2005) (72)
Transcriptomes of human prostate cells (2006) (70)
Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS‐2 in prostate cancer (1997) (70)
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. (2016) (69)
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. (2014) (69)
Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. (1998) (67)
Molecular and cellular characterization of ABCG2 in the prostate (2007) (66)
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate (2016) (66)
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. (2008) (65)
Is partial cystectomy the treatment of choice for mucinous adenocarcinoma of the urachus? (1997) (65)
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. (2019) (65)
An expressed-sequence-tag database of the human prostate: sequence analysis of 1168 cDNA clones. (1998) (64)
Small cell carcinoma of the bladder. Report of five cases with immunohistochemistry and review of the literature with evaluation of prognosis according to stage (1989) (63)
Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2015) (63)
Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. (2012) (62)
Morphometric applications in anatomic pathology. (1996) (62)
Placental bone morphogenetic protein (PLAB) gene expression in normal, pre‐malignant and malignant human prostate: Relation to tumor development and progression (2001) (61)
Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration (1996) (61)
I‐125 Versus Pd‐103 for Low‐Risk Prostate Cancer: Long‐Term Morbidity Outcomes From a Prospective Randomized Multicenter Controlled Trial (2005) (61)
Multicolor multicycle molecular profiling with quantum dots for single-cell analysis (2013) (60)
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. (2010) (60)
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration‐resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series (2013) (60)
Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. (2001) (59)
Long‐term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high‐risk features (2007) (58)
Differential expression of CD10 in prostate cancer and its clinical implication (2007) (58)
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer (2015) (58)
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases (2013) (57)
A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly. (2001) (57)
Keratin expression in normal esophageal epithelium and squamous cell carcinoma of the esophagus. (1985) (56)
Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes (2009) (56)
Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor–Dependent Manner (2009) (55)
Long‐term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma (2003) (54)
Analysis and sorting of prostate cancer cell types by flow cytometry (1999) (51)
Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine (2012) (50)
The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. (2003) (50)
Recurrent prostate cancer despite undetectable prostate specific antigen. (1992) (50)
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. (2002) (50)
Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. (1999) (49)
Testosterone Regulates Tight Junction Proteins and Influences Prostatic Autoimmune Responses (2011) (47)
Pathology residents' use of a Web-based tutorial to improve Gleason grading of prostate carcinoma on needle biopsies. (2000) (46)
Stromal mesenchyme cell genes of the human prostate and bladder (2005) (45)
Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. (2004) (45)
Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. (1997) (45)
Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies (2016) (45)
Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect (2010) (45)
Atlas of diagnostic immunohistopathology (1990) (45)
Expression of the human cachexia‐associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia (2003) (44)
Immunohistochemistry of Capillary Hemangioblastoma: Immunoperoxidase‐Labeled Antibody Staining Resolves the Differential Diagnosis with Metastatic Renal Cell Carcinoma, But Does Not Explain the Histogenesis of the Capillary Hemangioblastoma (1989) (43)
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia (2003) (42)
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. (2010) (42)
Harnessing non-destructive 3D pathology (2021) (42)
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist (2014) (42)
Odontogenic ghost cell carcinoma: a case report with immunohistochemical and ultrastructural characterization. (2007) (41)
Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy (2012) (41)
The expression of osteoclastogenesis‐associated factors and osteoblast response to osteolytic prostate cancer cells (2010) (41)
Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. (2003) (40)
Spermatocytic seminoma of testis with sarcomatous transformation. (1988) (40)
Urinary prostate specific antigen levels after radical prostatectomy. (1994) (40)
Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. (2014) (40)
Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer (2016) (40)
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer (2018) (39)
Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms. (2019) (39)
Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity (2015) (39)
Brachytherapy in men aged ≤ 54 years with clinically localized prostate cancer (2006) (38)
Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes (2009) (38)
Prostate cancer cell phenotypes based on AGR2 and CD10 expression (2012) (36)
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases (2013) (35)
Small cell carcinoma of the bladder. Report of five cases with immunohistochemistry and review of the literature with evaluation of prognosis according to stage. (1989) (35)
20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. (2005) (35)
Argon plasma coagulation for rectal bleeding after prostate brachytherapy. (2001) (35)
Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. (2015) (35)
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (2016) (34)
Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations (2016) (34)
Quantitative immunohistochemistry: a new tool for surgical pathology? (1988) (34)
Inhibition of angiopoietin‐2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability (2010) (33)
Utility of Pathology Imagebase for standardisation of prostate cancer grading (2018) (33)
Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients (2015) (33)
Male presenting with hoarseness and a thyroid mass. (1995) (33)
Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy (2010) (32)
Immunohistochemical characterization of a set of monoclonal antibodies to human neuron-specific enolase. (1988) (32)
Origin of granules in granular cell tumor. Intracellular myelin formation with autodigestion. (1988) (31)
Protease‐activated receptor‐1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis (2009) (31)
Kidney cancer in utility workers exposed to polychlorinated biphenyls (PCBs) (1989) (30)
Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes (2012) (29)
Open-Top Light-Sheet Microscopy Image Atlas of Prostate Core Needle Biopsies. (2019) (29)
Juvenile xanthogranulomas with inconspicuous or absent foam cells and giant cells (1991) (29)
Large cell carcinoma of the lung ultrastructural differentiation and clinicopathologic correlations (1985) (28)
The urologic epithelial stem cell database (UESC) – a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder (2007) (28)
Comparative Effectiveness of a Patient Centered Pathology Report for Bladder Cancer Care. (2016) (27)
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer (2017) (27)
Temporary PSA rises and repeat prostate biopsies after brachytherapy. (2001) (27)
Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. (2015) (26)
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
Tissue-of-origin-specific gene repositioning in breast and prostate cancer (2016) (26)
Development of the Minimum Information Specification for In Situ Hybridization and Immunohistochemistry Experiments (MISFISHIE). (2006) (26)
Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. (2004) (26)
Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes (2014) (25)
Preservation of feather fibers from the Late Cretaceous dinosaur Shuvuuia deserti raises concern about immunohistochemical analyses on fossils (2018) (25)
Hemangiopericytoma of breast: report of a case with ultrastructural and immunohistochemical findings. (1986) (23)
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi‐Institutional Radical Prostatectomy Cohort (2016) (23)
Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. (2008) (23)
Ciliated plantar cyst. (1980) (23)
Gene fusion analysis in renal cell carcinoma by FusionPlex RNA‐sequencing and correlations of molecular findings with clinicopathological features (2020) (22)
De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc (2020) (22)
The cancer nuclear microenvironment: Interface between light microscopic cytology and molecular phenotype (2008) (22)
A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers: The Canary Prostate Cancer Tissue Microarray (2013) (21)
Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice (2014) (21)
Differential Inductive Signaling of CD90+ Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells (2011) (21)
Prostate Cancer That Is Within 0.1 mm of the Surgical Margin of a Radical Prostatectomy Predicts Greater Likelihood of Recurrence (2014) (21)
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer (2019) (20)
Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports. (2014) (20)
Locus-specific gene repositioning in prostate cancer (2016) (20)
Thymic carcinoma associated with paraneoplastic polymyositis. (2009) (19)
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia (2021) (19)
Pathology Imagebase—a reference image database for standardization of pathology (2017) (19)
Dosimetry of an Extracapsular Anulus Following Permanent Prostate Brachytherapy (2007) (19)
Mismatch repair enzyme expression in primary and castrate resistant prostate cancer (2016) (19)
Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. (2007) (18)
Juvenile xanthogranulomas with inconspicuous or absent foam cells and giant cells. (1991) (18)
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study (2016) (18)
Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma. (2007) (18)
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer (2018) (18)
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. (2009) (18)
A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. (2013) (18)
Prostate Cancer–Associated Gene Expression Alterations Determined from Needle Biopsies (2009) (17)
WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence (2008) (17)
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer (2011) (17)
Analyzing Patterns of Staining in Immunohistochemical Studies: Application to a Study of Prostate Cancer Recurrence (2005) (16)
The Role of Tissue Microarrays in Prostate Cancer Biomarker Discovery (2007) (16)
Clinical correlates of high intraprostatic brachytherapy dose volumes. (2002) (16)
Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex. (2017) (16)
Advances in Brief Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS 2 1 (1999) (16)
High-dose regions versus likelihood of cure after prostate brachytherapy. (2005) (16)
Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). (2016) (16)
Readability of urologic pathology reports: the need for patient-centered approaches. (2014) (15)
Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. (2021) (15)
Flow cytometry analysis of proliferative lesions at the gastrocystoplasty anastomosis. (2003) (15)
A hybrid open-top light-sheet microscope for multi-scale imaging of cleared tissues (2020) (15)
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer (2020) (15)
The accumulation of versican in the nodules of benign prostatic hyperplasia (2009) (14)
Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. (2003) (14)
Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis (2021) (14)
Multiplexed functional genomic analysis of 5’ untranslated region mutations across the spectrum of prostate cancer (2021) (14)
Multi-resolution open-top light-sheet microscopy to enable efficient 3D pathology workflows. (2020) (14)
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. (2005) (14)
Immunohistochemical validation of expression microarray results. (2005) (14)
Tricuspid valve metastasis from testicular carcinoma: a case report and review of the literature. (2000) (14)
Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2 (2016) (13)
Iodine-125 vs palladium-103 for low-risk prostate cancer: Preliminary urinary functional outcomes from a prospective randomized multicenter trial (2000) (13)
Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity (2001) (13)
Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity (2004) (13)
The Prognostic Significance of Gleason Pattern 5 in Prostate Cancer Patients Treated with Pd 103 plus Beam Radiation Therapy (2004) (13)
Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling (2016) (12)
Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion (2019) (12)
CD38 in Advanced Prostate Cancers (2021) (12)
Image processing for the rest of us: the potential utility of inexpensive computerized image analysis in clinical pathology and radiology. (1989) (12)
How wide is the spectrum of neuroendocrine carcinoma of the urinary bladder? (2007) (12)
SRRM 4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer (2015) (12)
On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems. (2003) (11)
The Role of Electron Microscopy in the Management of Surgical Patients (1982) (11)
Multifaceted genitourinary lymphoma. (2008) (11)
A hybrid open-top light-sheet microscope for versatile multi-scale imaging of cleared tissues (2022) (11)
Solid immersion meniscus lens (SIMlens) for open-top light-sheet microscopy. (2019) (11)
Molecular and cellular characterization of ABCG 2 in the prostate (2007) (10)
Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. (2016) (10)
Fibroblast growth factor-10 signals development of von Brunn's nests in the exstrophic bladder. (2010) (10)
Pancreatic carcinoma metastatic to the mandibular gingiva. (1985) (10)
Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma. (2013) (10)
Isolated carcinoid tumor of the terminal filum. Case report. (2001) (10)
Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells (2022) (9)
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer (2021) (9)
The time for accurate Fuhrman grading of renal cell carcinomas has arrived. (2002) (9)
20 Gy Versus 44 Gy Supplemental Beam Radiation with Pd-103 Prostate Brachytherapy: Early Biochemical Outcomes From a Prospective Randomized Multi-Center Trial (2005) (9)
A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer (2016) (9)
Sporadic Oncocytic Tumors with Features Intermediate between Oncocytoma and Chromophobe Renal Cell Carcinoma: Comprehensive Clinico-Pathological and Genomic Profiling (2020) (8)
Diagnosing 12 prostate needle cores within an hour of biopsy via open-top light-sheet microscopy (2020) (8)
Neoadjuvant androgen pathway suppression prior to prostatectomy. (2012) (8)
Active surveillance for prostate cancer: the role of the pathologist. (2015) (8)
Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. (2003) (7)
The Prognostic Significance of Gleason Pattern 5 in Prostate Cancer Patients Treated With Pd-103 Brachytherapy (2007) (7)
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. (2018) (7)
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. (2020) (7)
Investigation of Doppler waveforms in porcine renal allografts: Doppler-pathologic correlation. (1988) (7)
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies (2022) (7)
Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy (2019) (7)
Erratum: Human cancers express a mutator phenotype (Proceedings of the National Academy of Sciences of the United States of America (November 28, 2006) 103, 48 (18238-18242) DOI: 10.1073/pnas.0607057103) (2006) (6)
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer (2022) (6)
Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations (2019) (6)
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. (2020) (6)
The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study (2019) (6)
The Time Gap Between Pd-103 Prostate Brachytherapy and Supplemental Beam Radiation Does Not Impact on Rectal Morbidity or Likelihood of Cure (2007) (5)
Brachytherapy versus brachytherapy plus beam radiation for prostate cancer: morbidity outcomes from two prospective randomized multicenter trials (2002) (5)
Prognostic biomarkers: an introduction (2014) (5)
Potentiation of the vasospastic response to angioplasty by pretreatment with fluoxetine. A study in the atherosclerotic rabbit. (1993) (5)
Aberrant hormone production from ovarian neoplasms: Strategies for diagnosis and therapy (1990) (5)
The antibiotic pipeline. (2004) (5)
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer (2021) (5)
The successful application of a local infusion Angioplasty catheter in a rabbit model of focal femoral atherosclerosis (1990) (5)
Why we must better understand neuroendocrine differentiation in prostate cancer. (2004) (5)
MP1-17 PTEN STATUS DETERMINATION IN PROSTATE CANCER: COMPARISON OF IHC AND FISH IN A LARGE MULTI-CENTER COHORT (2015) (4)
How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer? (2021) (4)
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for “large” cribriform prostatic adenocarcinoma (2022) (4)
Clinical problem solving: pathology. Pathology quiz case 1: benign parathyroid cyst. (2002) (4)
Report of a Sphenoid Sinus Lipoma (2012) (4)
PROSTATE CANCER BONE METASTASIS: REACTIVE OXYGEN SPECIES, GROWTH FACTORS AND HEPARAN SULFATE PROTEOGLYCANS PROVIDE A SIGNALING TRIAD THAT SUPPORTS PROGRESSION (2008) (3)
Paracrine Wnt signaling is necessary for prostate epithelial proliferation (2022) (3)
Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review (2017) (3)
Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices (2013) (3)
A challenge for the diagnostic immunohistopathologist. Adding the CD phenotypes to our diagnostic toolbox. (2003) (3)
Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial. (2010) (3)
Prostatic acid phosphatase predicts cancer-specific survival after Palladium-103 brachytherapy for prostate cancer (2007) (3)
Lack of microsatellite instability in human prostate-cancer. (1995) (3)
Prostate brachytherapy in patients with prior evidence of prostatitis. (1999) (3)
Upper airway obstruction caused by group G streptococcal laryngitis. (1995) (3)
Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2016) (3)
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. (2021) (3)
223 MITOCHONDRIAL DNA MUTATIONS INCREASE WITH METASTASIS IN PROSTATE CANCER (2010) (2)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. (2001) (2)
Parallel Array Method of Embedding Multiple Tissue Samples in a Single Paraffin Block (1991) (2)
Differential expression of CD 10 in prostate cancer and its clinical implication (2015) (2)
A challenge for the diagnostic immunohistopathologist (2003) (2)
Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate (2020) (2)
470: Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathologic Parameters and Biochemical Recurrence (2007) (2)
Prostate cancer risk stratification via non-destructive 3D pathology with annotation-free gland segmentation and analysis (2021) (2)
Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling (2021) (2)
THE LuCaP SERIES OF HUMAN PROSTATE CANCER XENOGRAFTS (1999) (2)
Development and Validation of a Quantitative Reactive Stroma Biomarker (qRS) for Prostate Cancer Prognosis. (2022) (2)
127 POSITIVE SURGICAL MARGINS AT RADICAL PROSTATECTOMY PREDICT PROSTATE CANCER-SPECIFIC MORTALITY: SUPPORT FOR OPTIMIZING SURGICAL TECHNIQUE AND PATHOLOGICAL EVALUATION AT RADICAL PROSTATECTOMY (2010) (2)
Brachytherapy in men ≤54 years of age with clinically localized prostate cancer (2006) (2)
An update on computational pathology tools for genitourinary pathology practice: A review paper from the Genitourinary Pathology Society (GUPS) (2022) (1)
Genomic characterization of ductal adenocarcinoma of the prostate. (2018) (1)
Comparative effectiveness of a patient-centered prostate biopsy report in clinical prostate cancer practice. (2018) (1)
Prostate-specific antigen: a clinical and mathematical conundrum. (2006) (1)
Long-term Prostate Cancer Control (13 Year Actuarial) in Patients with a High Likelihood of Extracapsular Cancer Extension Using PD-103 Brachytherapy and Supplemental Beam Radiation (2005) (1)
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) FOR DETECTION OF PROSTATE CANCER MICROMETASTASES IN PELVIC LYMPH NODES (LN), BONE MARROW (BM), AND PERIPHERAL BLOOD (PB) (1999) (1)
More accurate ways to measure tumor cellularity. (2014) (1)
Genitourinary cancer committee (2001) (1)
Rectal Doses Can Be Safely Minimized Without Affecting the Likelihood of Cure After Prostate Brachytherapy (2005) (1)
Urothelial dysplasia: Diagnostic value in clinical practice 20 years since the 1998 who/isup consensus (2020) (1)
Biology of lung cancer. Lung biology in health and disease, vol 37:Steven T. Rosen, James L. Mulshine, Frank Cuttitta, et al (eds). New York, Marcel Dekker, 1988, $99.50 (1989) (1)
Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations (2022) (1)
Contribution of mouse adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer xenografts. (2017) (1)
MP49-15 DOES TUMOR MICROENVIRONMENT AFFECT THE RESPONSE OF CASTRATION RESISTANT PROSTATE CANCER TO THERAPY IN BONE VS VISCERAL METASTASES? (2014) (1)
Endothelial cells in B-cell lymphomas. (2004) (1)
Abstract 305: The biological and molecular characterization of clinically relevant prostate cancer xenograft lines (LuCaP series), including responses to therapy. (2013) (1)
Abstract PO-017: Annotation-free 3D gland segmentation with generative image-sequence translation for prostate cancer risk assessment (2021) (1)
70‐YEAR‐OLD MAN WITH ENLARGED PINEAL GLAND (2008) (1)
Supplementary Material 10 (2014) (1)
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer (2023) (1)
Unusual Causes of Increased Vascular Impedance in Renal Transplants: Duplex Doppler Evaluation (1989) (1)
1029: Cancer to Total Prostate Volume Ratio Influences Patholgical Parameters and Biochemical Recurrence in Localized Prostate Cancer Treated by Radical Prostatectomy (2007) (1)
Method development and feasibility assessment for diagnosing 12 needle cores within an hour of biopsy (2020) (1)
Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) (1)
Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study. (2020) (1)
Multiplexed and quantitative study of biomarker expression in tumor specimens using quantum dots (2006) (1)
Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel (2005) (1)
Twenty-year trends in survival for metastatic kidney cancer. (2015) (0)
Prostate-specific antigen (2006) (0)
Abstract 804: Disseminated tumor cell heterogeneity and dormancy in prostate cancer. (2013) (0)
Abstract 1532: The identification of osteoblastic and osteolytic factors in prostate cancer bone metastases (2012) (0)
Publisher Correction: Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells (2022) (0)
The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy. (2006) (0)
541: CD90 As A Marker for Tumor-Associated Stromal Cells of the Prostate (2006) (0)
Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer. (2020) (0)
433: Increased Protease Activated Receptor (PAR) Expression and RhoA Signaling in Prostate Cancer (2004) (0)
erential Gene Expression in Benign Prostate Epithelium en with and without Prostate Cancer: Evidence (2010) (0)
Patient-Centered Pathology Reports for Breast Cancer Care: Interim Results of a Randomized Pilot Study (2020) (0)
Abstract 3302: Profiling prostate cancer metastases (2010) (0)
Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue. (2019) (0)
High quality brachytherapy dose distributions obviate the need for high dose supplemental external beam radiation in patients with higher risk features: Results of a prospective randomized trial (2008) (0)
P-09 Interactions between androgen receptor and BRCA1 in regulation of IGF-I receptor gene expression in prostate cancer cells (2008) (0)
Abstract 1989: SRRM4 and the loss of REST may promote the emergence of the neuroendocrine /neuronal phenotype in castration resistant prostate cancer (2014) (0)
Determination of the Intra-individual Variability of Protein Expression in Benign/Cancerous Prostate Tissue via LC-MS – Efforts Towards Molecular Classification (2013) (0)
Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data. (2020) (0)
Abstract 3242: The molecular and biological characterization of 25 unique prostate cancer xenograft lines, including response to therapy (2010) (0)
Male Reproductive System (2021) (0)
Prostate Cancer: Pathology and Genetics (2018) (0)
Abstract 406: Characterizing the molecular features of the neuroendocrine phenotype in castration resistant prostate cancer. (2013) (0)
SPATIALLY-RESTRICTED STROMAL WNT SIGNALING RESTRAINS PROSTATE EPITHELIAL PROGENITOR PROLIFERATION THROUGH DIRECT AND INDIRECT MECHANISMS (2019) (0)
Abstract 4392: Pre-mRNA splicing factors promote cellular plasticity in castration-resistant prostate cancer (2019) (0)
Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype (2018) (0)
Supplementary Material 8 (2013) (0)
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling (2021) (0)
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy (2019) (0)
20 Gy Versus 44 Gy Supplemental Beam Radiation With Pd-103 Prostate Brachytherapy: Preliminary Biochemical Outcomes From a Prospective Randomized Multi-Center Trial (2006) (0)
Benign parathyroid cyst (2002) (0)
Abstract 5249: LuCaP prostate cancer xenografts: Models that allow clinically relevant investigation of prostate cancer in a preclinical setting (2012) (0)
Tissue-of-origin-specific gene repositioning in breast and prostate cancer (2016) (0)
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC). (2019) (0)
The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study (2019) (0)
Pathology of prostate (2011) (0)
2210 DETECTION OF THE SECRETED PROSTATE CANCER BIOMARKER AGR2 IN VOIDED URINE (2012) (0)
Increased expression of CD44 and other cell surface molecules by cultured prostatic cells (1999) (0)
CLINICOPATHOLOGIC PREDICTORS OF TERTIARY GLEASON PATTERN 5 IN RADICAL PROSTATECTOMY SPECIMENS (2008) (0)
Abstract 5122: Characterizing the molecular features of ERG positive tumors in primary and castration resistant prostate cancer. (2013) (0)
MP6-13 PTEN LOSS BY IMMUNOHISTOCHEMISTRY IS ASSOCIATED WITH BIOCHEMICAL RECURRENCE IN ERG-NEGATIVE PROSTATE TUMORS: A STUDY OF THE CANARY COHORT (2015) (0)
The Prostate 70 : 1799 ^ 1808 ( 2010 ) InhibitionofAngiopoietin-2 in LuCaP 23 . 1 Prostate CancerTumorsDecreasesTumorGrowthandViability (2010) (0)
MP44-06 THE DEVELOPMENT AND COMPARATIVE EFFECTIVENESS OF A PATIENT CENTERED PROSTATE BIOPSY REPORT IN CLINICAL PRACTICE (2018) (0)
2501 ORAL A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer (2015) (0)
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy (2023) (0)
Harbingers of Aggressive Prostate Cancer: Precision Oncology Case Studies (2021) (0)
1124: Prostate Stromal Fibromuscular Cells Induce Differentiation in Embryocarcinomal Cell Line, NCCIT (2007) (0)
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial (2023) (0)
Title Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR 2 Permalink (2016) (0)
Identifying biomarkers specific to bone metastases in castrate-resistant prostate cancer. (2014) (0)
PATHOLOGIC STAGING OF PROSTATE CANCER: VARIABILITY IN IDENTIFYING HISTOPATHOLOGIC FEATURES (1999) (0)
Abstract 1583: The biological and molecular characterization of 24 unique prostate cancer xenograft lines, including responses to therapy (2011) (0)
724: A Database Tool and Minimum Information Specification for Prostate and Bladder Experimental Data (2004) (0)
Clinical Cancer esearch an Cancer Biology erential Gene Expression in Benign Prostate Epithelium en with and without Prostate Cancer : Evidence R a Prostate Cancer Field Effect (2010) (0)
Juvenile xanthogranulomas with absent foam cells and giant cells inconspicuous or (1991) (0)
308 Harnessing tumor localized IL-12 to enhance STEAP1 CAR T cell therapy for prostate cancer (2022) (0)
I-125 Versus Pd-103 for Low Risk Prostate Cancer: Morbidity Outcomes From a Prospective Randomized Multi-center Controlled Trial (2005) (0)
Abstract #5524: Chemotherapy-induced monoamine oxidase A expression in prostate carcinoma associates with clinical outcome and functions as a cytoprotective resistance enzyme through HIF1 pathway (2009) (0)
Lineage plasticity is a well–established mechanism of resistance to targeted therapies in lung and prostate cancer, where tumors transition from adenocarcinoma to small–cell or neuroendocrine carcinoma. Through single–cell analysis of a cohort of heavily–treated castration–resistant human prostate c (2021) (0)
Next generation clinical applications of open-top light-sheet microscopy (Conference Presentation) (2020) (0)
Abstract C34: The biological and molecular characterization of 28 unique prostate cancer xenograft lines (LuCaP series), including responses to therapy (2012) (0)
A mutator phenotype in human cancers: Origin and consequences. (2006) (0)
Title : The Androgen-Regulated Protease TMPRSS 2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis (2014) (0)
332 PROSTATE CANCER DISSEMINATED TUMOR CELL HETEROGENEITY AND DORMANCY (2013) (0)
Expression of Epidermal Growth Factor Receptor Distinguishes Chromophobe Renal Cell Carcinoma From Most Oncocytomas (2012) (0)
Deep Learning-assisted 3D Segmentation and Analysis of Prostate Glands for Cancer Risk Stratification (2022) (0)
Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS). (2022) (0)
MP04-02 ANALYSIS OF EX-VIVO HUMAN BPH TISSUE TREATED BY HISTOTRIPSY: DOSE AND PARAMETER EFFECTS (2022) (0)
CLINICAL PROBLEM SOLVING: PATHOLOGY (2016) (0)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Pathology Committee. (2001) (0)
Annotation-free 3D segmentation of prostate glands enabled with deep-learning image translation (2021) (0)
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (2015) (0)
Prostate Specific Antigen (PSA) Screening and a Lifesaving Cardiac Transplant. (2022) (0)
Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity (2022) (0)
Abstract 2200: Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling (2022) (0)
Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. (2018) (0)
Open-top light-sheet (OTLS) fluorescence microscopy image atlas of prostate core-needle biopsies (2020) (0)
1641 PROSTATE CANCER < 2 CELLS FROM THE SURGICAL MARGIN PREDICTS BIOCHEMICAL RECURRENCE (2012) (0)
Abstract 989: Spatial profiling of androgen receptor splice variant 7 transcriptional activity in prostate cancer metastases (2022) (0)
2134 DIFFERENTIAL EXPRESSION OF AGR2 AND CD10 IN PROSTATE CANCER (2013) (0)
Comprehensive surface histology of fresh resection margins with rapid open-top light-sheet (OTLS) microscopy. (2023) (0)
Abstract 1092: Defining the molecular phenotypes of metastatic castration-resistant prostate cancer sensitive to FGF pathway inhibition (2018) (0)
1609: Pelvic Lymphadenectomy in Radical Prostatectomy: Defining True Number of Nodes and Extent of Metastatic Prostate Cancer (2005) (0)
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource (2021) (0)
Commentary Immunohistochemical Validation of Expression Microarray Results (2005) (0)
Urologic Surgical Pathology (1998) (0)
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy (2022) (0)
FGF and MAPK pathways are active in AR-null prostate cancer d Autocrine and paracrine FGF pathway activation can bypass AR dependence d Targeting the FGF and MAPK pathways can repress AR-null prostate cancer (0)
INCIDENCE AND SURVIVAL OF RARE HISTOLOGIC SUBTYPES OF PROSTATE CANCER OVER A 30-YEAR PERIOD (2008) (0)
665 EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY (2013) (0)
Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes (2012) (0)
Inside the USCAP Journals (2022) (0)
Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations. (2019) (0)
Reply by Authors. (2023) (0)
1095: CD10 Expression Correlates with a Higher Risk for Lymph Node Metastasis in Human Prostate Cancer (2004) (0)
Sarcomatoid Urothelial Carcinoma is Associated with Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes after Radical Cystectomy (2023) (0)
Method development and feasibility assessment for diagnosing 12 prostate needle cores within an hour of biopsy (2021) (0)
251: Transcriptomes of Human Prostate Cells (2006) (0)
RIS 1 GTAAGCCCATTGAGTCCACGC TCACTTGGTCGCCACCCCCGA ChGn TGCAGCAGTGCCTTTCGATAG GTCGAAATAAGATGAGCCGTTTGA TNC CAGACATCACTGAAAATTCGGCTAC GCAAAGATTCTCAGTGTGTATTCCG EDNRB GCAAACCGCAGAGATAATGACG TCAAGATATTGGGACCGTTTCG STC 2 CAAGTCATTCATCAAAGACGCCTT CCTTTCATTTCACCTCCGGATATC BF ACTCCATGGTCTTTGGCCCAG AGTGGATTG (2015) (0)
Preservat ion of feather fibers from the Late Cretaceous dinosaur Shuvuuia desert i raises concern about immunohistochemical analyses on fossi ls (2018) (0)
Abstract 1718: The importance of clinically relevant rapid autopsy specimens and LuCaP patient-derived xenograft models to interrogate the heterogeneous and evolving treatment resistance of castration-resistant prostate cancer (2015) (0)
Abstract 5059: Exome and targeted sequencing to discover and validate candidate genes in advanced and lethal prostate cancer (2012) (0)
A Clinical and Mathematical Conundrum (2006) (0)
Assessing the Risk of Pathologic Lymph Node Involvement in Intermediate Risk Prostate Cancer. (2021) (0)
Spatially Restricted Strom al Wnt Signaling Restrains Prostate Epithelial Progenitor Growth throughDirect and Indirect Mechanisms Graphical (2019) (0)
MP37-04 PILOT EVALUATION OF A PATIENT-CENTERED PROSTATE BIOPSY PATHOLOGY REPORT (2016) (0)
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. (2018) (0)
A genotoxic antibody drug conjugate targeting CD276/B7H3 demonstrates efficacy across multiple biomarker defined classes of treatment refractory metastatic prostate cancer (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence D. True?

Lawrence D. True is affiliated with the following schools:

Yale University
Oregon Health & Science University
University of Washington